Christine Norred
Optometrist · Baton Rouge, LANPI 1013949833
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,891 of the $6,044 with a category attached, or 80.9%. 18 manufacturers reported payments, led by Alcon at 34.7% of the total. Among optometrist clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 146 payments — averaging $41.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Johnson & Johnson Vision Care, Inc.$849
- AbbVie$733
- Bausch & Lomb Americas Inc.$410
- Sun Pharmaceutical Industries Inc.$390
- Glaukos Corporation$360
- plus $1K from 12 others
What the payments were for
- Travel & lodging$1,15319%
- Food & beverage$4,89181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 21 | $2,097 |
| Johnson & Johnson Vision Care, Inc. | 30 | $849 |
| AbbVie(2 entities) | 22 | $733 |
| Bausch & Lomb Americas Inc. | 12 | $410 |
| Sun Pharmaceutical Industries Inc. | 21 | $390 |
| Glaukos Corporation | 8 | $360 |
| Tarsus Pharmaceuticals, Inc. | 10 | $220 |
| Harrow Eye, LLC | 3 | $179 |
| Biotissue Holdings Inc. | 4 | $140 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $138 |
| Mallinckrodt Hospital Products Inc. | 1 | $117 |
| Dompe US, Inc. | 1 | $117 |
| Ocular Therapeutix, Inc. | 1 | $100 |
| Eyevance Pharmaceuticals LLC | 3 | $55 |
| Coopervision Inc. | 3 | $45 |
| Oyster Point Pharma, Inc. | 2 | $35 |
| Novartis | 2 | $35 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIR OPTIX$1,358
- DAILIES$956
- DAILIES TOTAL1 Multifocal$740
- Dailies Aqua Comfort Plus$740
- Tecnis IOL$138
- XEN$125
- Acuvue$125
- iDoseTR$125
- VEVYE$124
- TRYPTYR$122
- ACTHAR$117
- Oxervate$117
- INFUSE$117
- BIOTRUE ONE DAY$117
- VUITY$103
- INFUSE MULTIFOCAL$101
- DEXTENZA$100
How this compares
$6,044 in reported general payments places this provider in the 90th percentile of 500 optometrist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 180 | $143,832 |
| XdemvyLotilaner | 12 | $22,398 |
| LumiganBimatoprost | 23 | $9,682 |
| CequaCyclosporine | 17 | $9,587 |
| Azelastine Hcl | 197 | $5,473 |
| ZerviateCetirizine Hcl | 18 | $4,844 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 20 | $4,067 |
| Cyclosporine | 18 | $3,339 |
| Loteprednol Etabonate | 12 | $2,102 |
| Latanoprost | 199 | $1,494 |
| Fluorometholone | 20 | $1,423 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 100 | $1,312 |
| Prednisolone Acetate | 16 | $554 |
| ErythromycinErythromycin Base | 41 | $497 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 30 | $470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $733 | $153,513203 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $220 | $22,39812 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $390 | $9,58717 claims |
| Eyevance Pharmaceuticals LLCZerviate | $55 | $4,84418 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $24 | $2,10212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 500 optometrist providers in Louisiana.
Other optometrist in Baton Rouge
- Eric ThaiBaton Rouge$7K
- Kevin DuongBaton Rouge$7K
- Khanh TrinhBaton Rouge$7K
- Shonda AchordBaton Rouge$6K
- Hannah ChustzBaton Rouge$6K
- Pamela TheriotShreveport$207K
- Joshua DavidsonGonzales$189K
- Jeffrey WilhiteMarrero$86K
- Christopher WrotenHammond$59K
- James LamarNew Orleans$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.